Clinical trial · Interventional
Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
Prospective Study Comparing Lipiodol Plus Ethanol Solution Compared With Drug-Eluting Beads for Trans-arterial Chemoembolization of Liver in Treatment of Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Insufficient staff
Summary
Brief summary (as posted)
Chemoembolization of hepatocellular carcinoma lesions is an accepted and frequently used method for the palliative or curative treatment of these lesions. These attempts are being made to make these patients a better candidate for liver transplant or to provide palliation for their condition.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Drug-Eluting Beads (DEB) with Doxorubicin | Drug | — | UNRESOLVED |
| Lipiodol Ethanol Mixture | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Drug-Eluting Beads with Doxorubicin
- description
- Drug-Eluting Beads (DEB) with Doxorubicin is administered via beads that release it to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
- interventionNames
- Drug: Drug-Eluting Beads (DEB) with Doxorubicin
- type
- ACTIVE_COMPARATOR
- label
- Lipiodol Ethanol Mixture (LEM)
- description
- Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered via catheter through the vessels that feed the liver.
- interventionNames
- Drug: Lipiodol Ethanol Mixture
Primary outcomes (1)
- measure
- Number of Patients with Post-Embolization Syndrome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Child-Pugh class A or B * Biopsy proven HCC or hypervascular mass per European Association for the Study of the Liver (EASL) criteria * Patient not a candidate for surgical resection or percutaneous ablation * age \> 18 years old and able to consent Exclusion Criteria: * Child-Pugh class C * Model for End-Stage Liver Disease (MELD) score \>16 * Extrahepatic disease * Bilateral or main portal vein thrombus * Total bilirubin \> 2.2 * Serum albumin \< 2.6 * Life expectancy \< 2 months * Uncorrected INR \> 2 * Eastern Cooperative Oncology Group (ECOG) status \> 2 * Tumor burden \> 50% liver volume * Hepatofugal portal venous flow
References
Publications (0)
Data not yet available